๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 13 Wuhan 2 Tianjin 1 Fuzhou 1 Ningbo 1
Narrow the registerReset
Recruitment status
Phase
Site location
Guangzhou13 Wuhan2 Tianjin1 Fuzhou1 Ningbo1
All 18 locations
Target enrolment
to

Trials with a site in Guangzhou

13 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT
NCT06904183Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
320
Guangzhou
2025-04-01
Recruiting
Lenvatinib Plus SIRT vs Lenvatinib in TACE-Refractory HCC
NCT06904196Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
78
Guangzhou
2025-04-01
Active, closed
Chemotherapy With the Ralox Regimen Combined With Anlotinib and Penpulimab for Unresectable Hepatocellular Carcinoma
NCT07746960Hepatocellular Carcinoma Non-Resectable
Nanfang Hospital, Southern Medical University
Phase EARLY_PHASE1
30
Guangzhou
2025-01-01
Not yet open
A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma
NCT06779461Hepatocellular Carcinoma Non-Resectable
InnoBM Pharmaceuticals Co., Ltd.
Phase 3
228
Bengbu, Anyang, Zhengzhou, Nanjing, Lishui, Guangzhou, Lanzhou, Luoyang
2025-01
Recruiting
Y-90 SIRT for Unresectable HCC Larger Than 7cm
NCT06707233Hepatocellular Carcinoma Non-Resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
33
Guangzhou
2024-12-01
By invitation
Observational Study for SIR-Spheres Therapy for the Treatment of HCC Patients in China
NCT06712017Hepatocellular Carcinoma (HCC), Hepatocellular Carcinoma Non-Resectable
GrandPharma (China) Co., Ltd.
Observational
100
Guangzhou, Jinan, Xiโ€™an, Beijing, Shanghai
2024-08-22
Recruiting
Lenvatinib Plus DEB-TACE and HAIC vs. Lenvatinib Plus DEB-TACE for Large HCC With PVTT
NCT06492395Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
178
Guangzhou
2024-08-01
Recruiting
DEB-TACE+RALOX-HAIC vs DEB-TACE for Large HCC
NCT06397235Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
130
Guangzhou
2024-05-01
Recruiting
Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC
NCT06397222Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
23
Guangzhou
2024-05-01
Recruiting
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
NCT06607107Hepatocellular Carcinoma Non-resectable
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
29
Guangzhou
2024-02-17
Recruiting
Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC
NCT05985798Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
258
Guangzhou
2023-08-01
Recruiting
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
NCT05608200Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
427
Guangzhou
2022-11-02
Recruiting
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
NCT05608213Hepatocellular Carcinoma Non-resectable
Second Affiliated Hospital of Guangzhou Medical University
Phase 3
187
Guangzhou
2022-11-02
Rows per page Showing 1–13 of 13
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 13 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

10 of the 13 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 13 studies
PhaseStudiesRecruitingShare
Phase 26646.2%
Phase 35438.5%
Observational107.7%
Phase EARLY_PHASE1107.7%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Guangzhou Medical University99
GrandPharma (China) Co., Ltd.10
InnoBM Pharmaceuticals Co., Ltd.10
Nanfang Hospital, Southern Medical University10
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.